PROGRAM CHAIRS
George L. Bakris, MD, FASH, FASN, FAHA
Professor of Medicine
Director, AHA Comprehensive Hypertension Center
University of Chicago
Chicago, IL
Robert D. Toto, MD
Professor of Medicine
Associate Dean for Clinical and Translational Research
University of Texas Southwestern Medical Center
Dallas, TX
This event is not part of the official Internal Medicine Meeting 2024 Education Program. CME credit is provided by organizations other than ACP.
PROGRAM OVERVIEW
This enduring symposium is designed to meet the educational needs of primary care clinicians working with a multidisciplinary team of cardiologists, nephrologists, nurses, pharmacists, and other healthcare providers who care for patients with diabetes to ensure recognition of chronic kidney disease (CKD) risk and institute novel strategies for modifying the risk of CKD and other chronic complications of T2D.
TARGET AUDIENCE
This activity is designed to meet the educational needs of primary care and internal medicine physicians and their clinical teams, including nurse practitioners, physician assistants, and pharmacists.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Assess the mechanistic features of agents indicated to reduce the risk of CKD progression, such as SGLT2 inhibitors and MRAs
- Recognize current clinical data and guidelines informing the management of CKD risk across patient groups
- Evaluate updates concerning management of adverse events associated with therapy to reduce the risk of CKD progression, including review of best practices in adverse event monitoring and management
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
Pharmacists and Pharmacy Technicians (ACPE) Credit Designation
Med Learning Group designates this activity for a maximum of 1.0 knowledge-based CPE contact hour.
NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 45 days of your participation in the activity to meet the deadline for submission to CPE Monitor. Credits are generally reported during the first week of each month for those who claimed during the month prior.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| George L. Bakris, MD | Consulting Fee: Bayer, Novo Nordisk, ESTAR, and AstraZeneca |
| Robert D. Toto, MD | Consulting Fee: AstraZeneca, Bayer HealthCare Pharmaceuticals, Boehringer Engelheim, and Janssen Pharmaceuticals |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Shannon Mutch MS, RN, OCN, has nothing to disclose.
- Michael Milano, MD, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Debra Gordon, Medical Director for Med Learning Group, has nothing to disclose.
- Ana Maria Albino, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Jessica Feygin-Samuels, Associate Program Manager for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Daniel Dasilva, Accreditation and Outcomes Coordinator, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected].
RELEASED DATE: April 25, 2024
EXPIRATION DATE: April 25, 2025
Copyright ©2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
